Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 20;50(1):102.
doi: 10.1186/s13052-024-01670-5.

Impact of COVID-19 pandemic on prescription of psychotropic medications in the Italian paediatric population during 2020

Francesca Gallinella  1 , Francesco Trotta  1 , Filomena Fortinguerra  2
Affiliations

Impact of COVID-19 pandemic on prescription of psychotropic medications in the Italian paediatric population during 2020

Francesca Gallinella et al. Ital J Pediatr. .

Abstract

Background: There is a global perception that psychotropic utilization in children and adolescents is increasing, especially with the onset of COVID-19 pandemic. Available literature data on paediatric psychotropic medication prescriptions in Italy are limited to one or few regions and not updated. The aim of this study was to provide updated data on psychotropic prescriptions referred to the whole Italian paediatric population, as overall and by subgroups of medications and to evaluate if the COVID-19 pandemic during 2020 had an impact on prescription rates.

Methods: A descriptive study on psychotropic drug utilization in children and adolescents (< 18 years) resident in all Italian regions during 2020 was performed. Patients registered in the Pharmaceutical Prescriptions database with at least one prescription/dispensing of a psychotropic medication (antipsychotics-N05A), (antidepressants-N06A) and (psychostimulants-N06BA) during the study period were considered. The indicators used were the prescription rate (number of prescriptions per 1000 children) and prevalence of use (proportion of the paediatric population with at least one prescription in the relevant year).

Results: During the 2020 the prevalence of psychotropic drug use in the paediatric population was 0.3%, increased of 7.8% if compared to 2019. The same trend was observed for the prescription rate, which recorded an average of 28.2 per 1000 children with an increase of 11.6% if compared to previous year, representing the 0.6% of the overall drug use in this age group. The data showed a growing trend prescription by age, reaching the peak in adolescents aged 12-17 years old, with a prescription rate of 65 per 1000 children and a prevalence of 0.71%. Considering the subgroups of psychotropic medications, the highest prevalence of use was found for antipsychotic drugs, received by the 0.19% of the paediatric population during 2020.

Conclusions: Psychotropic drug utilization in children and adolescents has grown during 2020 in Italy and worldwide, raising alarms from health care clinicians and patient advocates about the increase of burden of mental diseases in paediatric population during the COVID-19 pandemic. A more systematic monitoring of the use of psychotropic medications should be implemented in all countries for collecting relevant information about children and adolescents taking psychotropic drugs, in order to address the present and the future of the mental health of the paediatric population.

Keywords: Adolescent; Child; Drug utilization; Outpatients; Psychotropic drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Prevalence (%) and prescriptions rate (N. per 1000 inhabitants) of psychotropic medications in paediatric population by age class during 2020
Fig. 2
Fig. 2
Distribution (%) of psychotropic medication prescriptions in paediatric population by age class during 2020
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization (WHO). Adolescent mental health, 17 november 2021. https://www.who.int/news-room/fact-sheets/detail/adolescent-mental-health. Accessed 18 January 2024.
    1. Collaborators GBDMD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Psychiatr. 2022;9:137–50. doi: 10.1016/S2215-0366(21)00395-3. - DOI - PMC - PubMed
    1. Piao J, Huang Y, Han C, Li Y, Xu Y, Liu Y, He X. Alarming changes in the global burden of mental disorders in children and adolescents from 1990 to 2019: a systematic analysis for the Global Burden of Disease study. Eur Child Adolesc Psychiatry. 2022;31(11):1827–45. doi: 10.1007/s00787-022-02040-4. - DOI - PubMed
    1. Frigerio A, Rucci P, Goodman R, Ammaniti M, Carlet O, Cavolina P, et al. Prevalence and correlates of mental disorders among adolescents in Italy: the PrISMA study. Eur Child Adolesc Psychiatry. 2009;18(4):217–26. doi: 10.1007/s00787-008-0720-x. - DOI - PubMed
    1. Panchal U, Salazar de Pablo G, Franco M, Moreno C, Parellada M, Arango C, Fusar-Poli P. The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. Eur Child Adolesc Psychiatry. 2023;32(7):1151–77. doi: 10.1007/s00787-021-01856-w. - DOI - PMC - PubMed